Brief: Guardant Health Announces Approval In Europe Of Guardant360® Cdx
BRIEF-Guardant Health Announces Approval In Europe Of Guardant360® Cdx Oct 8 (Reuters) - Guardant Health, Inc. GH.O:
GUARDANT HEALTH ANNOUNCES APPROVAL IN EUROPE OF GUARDANT360® CDX AS COMPANION DIAGNOSTIC FOR ASTRAZENECA’S ETCAMAH™ (CAMIZESTRANT) IN ADVANCED ER-POSITIVE BREAST CANCER
Source text: ID:nBwbqjLxja
Further company coverage: GH.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on AstraZeneca
See all newsAstraZeneca fends off lawsuit over alleged Soliris drug monopoly (updated)
AstraZeneca fends off lawsuit over alleged Soliris drug monopoly
Sofinnova closes €725 million fund to back European biotech expansion
AstraZeneca gets US nod for expanded Imfinzi use, new rare-disease therapy
UK Stocks-Factors to watch on November 16 (updated)